{Reference Type}: Case Reports
{Title}: Sirolimus treatment for neonate with blue rubber bleb nevus syndrome: A case report.
{Author}: Yang SS;Yang M;Yue XJ;Tou JF;
{Journal}: World J Clin Cases
{Volume}: 9
{Issue}: 23
{Year}: Aug 2021 16
{Factor}: 1.534
{DOI}: 10.12998/wjcc.v9.i23.6929
{Abstract}: <B>BACKGROUND: </B>Blue rubber bleb naevus syndrome (BRBNS) is a rare disease that usually presents with multiple venous malformations in the skin and gastrointestinal tract. Lesions located in the gastrointestinal tract always result in chronic gastrointestinal bleeding and severe anemia. The successful management of BRBNS with sirolimus had been reported in many institutions, due to its impact on signaling pathways of angiogenesis. However, the experience in treatment of neonates with BRBNS was limited.<BR><B>METHODS: </B>A 38-day-old premature female infant born with multiple skin lesions, presented to our center complaining of severe anemia and hematochezia. Laboratory examination demonstrated that hemoglobin was 5.3 g/dL and contrast-enhanced abdominal computed tomography showed multiple low-density space-occupying lesions in the right lobe of the liver. She was diagnosed as having BRBNS based on typical clinical and examination findings. The patient was treated by transfusions twice and hemostatic drugs but symptoms of anemia were difficult to alleviate. A review of BRBNS case reports found that patients had been successfully treated with sirolimus. Then the patient was treated with sirolimus at an average dose of 0.95 mg/m2/d with a target drug level of 10-15 ng/mL. During 28 mo of treatment, the lesion was reduced, hemoglobin returned to normal, and there were no adverse drug reactions.<BR><B>CONCLUSIONS: </B>This case highlights the dosing regimen and plasma concentration in neonates, for the current common empiric dose is high.